Politics
FDA Delays Mifepristone Review
The FDA announced it will not publish its safety review of the abortion drug mifepristone until March, drawing criticism from anti-abortion advocates. The decision comes amid ongoing political debates surrounding reproductive rights.
Coverage timeline — 1 article
The Hill
The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion ac
2026-10-08 02:33 UTC